Mount Sinai Is First to Use FDA-Approved Drug-Eluting Stent That Treats Peripheral Artery Disease
Vascular specialists at the Icahn School of Medicine at Mount Sinai are the first in the United States to use the Eluvia™, a drug-eluting vascular stent system for clinical treatment of peripheral artery disease (PAD), a circulatory condition that causes a narrowing of the blood vessels and a reduction of blood flow to the limbs.
According to the U.S. Centers for Disease Control and Prevention, 8.5 million people in the country have PAD; men and woman are equally affected by the disease. PAD most commonly affects arteries in the legs and is caused by a buildup of plaque that restricts blood flow and causes pain and swelling. If left untreated, PAD can lead to gangrene and amputation.
Eluvia, a vascular stent system developed by Boston Scientific, is a polymer-coated stent that delivers drug therapy for 12 months, the time period when restenosis (narrowing of an artery after corrective procedure) is most likely to occur. As results showed in the IMPERIAL clinical trial, recently published in The Lancet, patients treated with the Eluvia stent experienced a greater 12-month primary patency (expansion of blood vessels) of 88.5 percent compared to 79.5 percent in patients treated with Zilver®PTX®, a competing stent system.
“Mount Sinai has been on the cutting edge of all new endovascular techniques and technology, and our institution was one of the first to use drug-eluting stents for the treatment of peripheral arterial disease,” said Robert Lookstein, MD, Professor of Radiology and Surgery and Vice Chair of the Department of Radiology. “Our team is excited to offer this new treatment to patients suffering from this terrible disease.”
Vascular and endovascular specialists at Mount Sinai perform thousands of endovascular procedures each year and offer a full range of minimally invasive therapies for peripheral vascular disease, including therapies for lower limb arterial circulation, venous disorders, and aneurysmal disease.
Dr. Lookstein receives compensation as an advisory board member and consultant to Boston Scientific.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.